At the start of 2019, the chief executive of one of the generics industry’s biggest players set out a bold claim: that the severe US pricing pressures experienced over the past few years had stabilized, bringing an end to a period of misery for many generics producers.
“The whole pricing dynamic in US generics [has] changed,” Teva Pharmaceutical Industries Ltd. president and chief executive officer Kåre...